Intrexon is a gene expression and regulation company focused on control of cells and organisms that is headquartered in Germantown, Maryland and was founded in 1998. The company is developing technology for biological systems across four major biology classes - Microbes, Plants, Animals, Human Cells - to protect the environment, promote health, and feed the growing populations of humans and animals. The company is also developing gene and cell therapies using precision immunology. Intrexon is using several technologies to develop their products which give them the capability to precisely control gene expression, design and engineer biosystems, and engineering gene function and delivery.
On January 23, 2017 Intrexon acquired a gene therapy company called GenVec for approximately $15.9 million. The deal gave stockholders of GenVec 0.297 of an Intrexon share for each share of GenVec common stock based on Intrexon's five-day weighted average as of January 23, 2017.
